1. Home
  2. IMSR vs CABA Comparison

IMSR vs CABA Comparison

Compare IMSR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMSR

Terrestrial Energy Inc.

N/A

Current Price

$6.42

Market Cap

233.8M

Sector

N/A

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.04

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMSR
CABA
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.8M
319.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
IMSR
CABA
Price
$6.42
$3.04
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
1.2M
2.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.95
$0.99
52 Week High
$16.38
$3.78

Technical Indicators

Market Signals
Indicator
IMSR
CABA
Relative Strength Index (RSI) 40.99 48.95
Support Level $5.98 $2.11
Resistance Level $7.59 $3.34
Average True Range (ATR) 0.57 0.26
MACD 0.07 -0.04
Stochastic Oscillator 26.11 13.22

Price Performance

Historical Comparison
IMSR
CABA

About IMSR Terrestrial Energy Inc.

Terrestrial Energy Inc is an industry-leading technology company committed to delivering reliable, emission-free, and cost-competitive nuclear energy with a transformative advanced reactor, the Integral Molten Salt Reactor (IMSR). Its mission is to transform global energy markets by commercializing its IMSR Plant, which will deliver low-carbon electricity and industrial heat with superior economics, speed to deployment, and siting flexibility.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: